Reported Late Wednesday, Liminatus Pharma And Iris Acquisition Corp To Combine To Incorporate And Accelerate Much-Needed Cancer Treatments
Businesses announce Definitive Business Combination Agreement and plan to operate under Liminatus Pharma
The transaction values the combined companies at a pro forma enterprise value of $334